Development of the Sm14/GLA-SE Schistosomiasis Vaccine Candidate: An Open, Non-Placebo-Controlled, Standardized-Dose Immunization Phase Ib Clinical Trial Targeting Healthy Young Women

We report the successful closure of Phase I clinical trials, comprising Phases Ia and Ib, of the vaccine candidate against human schistosomiasis: the Schistosoma mansoni 14 kDa fatty acid-binding protein (Sm14) + glucopyranosyl lipid A in squalene emulsion (GLA-SE). Shown here are the results of Pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Santini-Oliveira, Marília, Machado Pinto, Patrícia, dos Santos, Tatiane, Vilar, Mônica Magno, Grinsztejn, Beatriz, Veloso, Valdilea, Paes-de-Almeida, Elan C., Amaral, Maria A. Z., Ramos, Celso R., Marroquin-Quelopana, Miryam, Coler, Rhea, Reed, Steven, Ciol, Marcia A., Savino, Wilson, Parra, Juçara de Carvalho, Almeida, Marília Sirianni dos Santos, Tendler, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607179/
https://www.ncbi.nlm.nih.gov/pubmed/36298589
http://dx.doi.org/10.3390/vaccines10101724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607179/
https://www.ncbi.nlm.nih.gov/pubmed/36298589
http://dx.doi.org/10.3390/vaccines10101724

Ejemplares similares